Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds expression product or fragment thereof of...
Reexamination Certificate
2004-04-26
2011-10-18
Canella, Karen (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds expression product or fragment thereof of...
C424S141100, C424S156100
Reexamination Certificate
active
08038994
ABSTRACT:
Disclosed are methods for treating cancer comprising administering a xenotypic antibody and a chemotherapeutic drug to a patient suffering from cancer. Also disclosed is a method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen present in the host serum, which antigen does not elicit an effective host immune response, comprising administering to the patient a chemotherapeutic drug and a composition comprising a binding agent that specifically binds to a first epitope on the antigen and allowing the binding agent to form a binding agent/antigen pair, wherein an effective host immune response is elicited against a second epitope on the antigen.
REFERENCES:
patent: 3865689 (1975-02-01), Goldenberg
patent: 4331647 (1982-05-01), Goldenberg
patent: 4348376 (1982-09-01), Goldenberg
patent: 4471057 (1984-09-01), Koprowski et al.
patent: 4740371 (1988-04-01), St. Remy et al.
patent: 4879225 (1989-11-01), Morgan, Jr. et al.
patent: 4940670 (1990-07-01), Rhodes
patent: 4950480 (1990-08-01), Barber et al.
patent: 4975278 (1990-12-01), Senter et al.
patent: 4997762 (1991-03-01), Hanna, Jr. et al.
patent: 5009888 (1991-04-01), Dunn
patent: 5013547 (1991-05-01), Sweet et al.
patent: 5053224 (1991-10-01), Koprowski et al.
patent: 5075218 (1991-12-01), Jette et al.
patent: 5165922 (1992-11-01), Hellstrom et al.
patent: 5183657 (1993-02-01), Buurman
patent: 5194254 (1993-03-01), Barber et al.
patent: 5240833 (1993-08-01), Nudelman et al.
patent: 5308614 (1994-05-01), Hakomori
patent: 5389530 (1995-02-01), Hakomori
patent: 5478556 (1995-12-01), Elliott et al.
patent: 5500215 (1996-03-01), Hakomori
patent: 5506343 (1996-04-01), Kufe
patent: 5512283 (1996-04-01), Byers et al.
patent: 5518723 (1996-05-01), Devico et al.
patent: 5530101 (1996-06-01), QuEn et al.
patent: 5532159 (1996-07-01), Webb et al.
patent: 5583202 (1996-12-01), Zanetti
patent: 5591593 (1997-01-01), Courtenay-Luck
patent: 5652114 (1997-07-01), Chu et al.
patent: 5683674 (1997-11-01), Taylor-Papadimitriou et al.
patent: 5688657 (1997-11-01), Tsang et al.
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5726023 (1998-03-01), ChEver et al.
patent: 5783186 (1998-07-01), Arakawa et al.
patent: 5807978 (1998-09-01), Kokolus et al.
patent: 5869445 (1999-02-01), Cheever et al.
patent: 5933439 (1999-08-01), Hyuga et al.
patent: 5972347 (1999-10-01), Eder et al.
patent: 5976818 (1999-11-01), O'Brien
patent: 5977316 (1999-11-01), Chatterjee et al.
patent: 5997869 (1999-12-01), Goletz et al.
patent: 6068830 (2000-05-01), Diamandis et al.
patent: 6077519 (2000-06-01), Storkus et al.
patent: 6080557 (2000-06-01), Sims et al.
patent: 6086873 (2000-07-01), Sykes et al.
patent: 6088613 (2000-07-01), Unger
patent: 6096289 (2000-08-01), Goldenberg
patent: 6123939 (2000-09-01), Shawver et al.
patent: 6140091 (2000-10-01), Raso et al.
patent: 6258358 (2001-07-01), Romet-Lemonne et al.
patent: 6358976 (2002-03-01), Wityak et al.
patent: 6881405 (2005-04-01), Leveugle et al.
patent: 7198928 (2007-04-01), Liang et al.
patent: 7238786 (2007-07-01), Gold et al.
patent: 2001/0036457 (2001-11-01), Madiyalakan et al.
patent: 2002/0022235 (2002-02-01), Noujaim
patent: 2002/0173629 (2002-11-01), Jakobovits et al.
patent: 2005/0048059 (2005-03-01), Madiyalakan et al.
patent: 2005/0063976 (2005-03-01), Schultes et al.
patent: 2005/0260208 (2005-11-01), Eng et al.
patent: 2006/0159688 (2006-07-01), Madiyalakan et al.
patent: 2007/0036798 (2007-02-01), Madiyalakan et al.
patent: 2007/0092522 (2007-04-01), Noujaim
patent: 2008/0131443 (2008-06-01), Madiyalakan et al.
patent: 2008/0206318 (2008-08-01), Madiyalakan
patent: 2008/0220012 (2008-09-01), Madiyalakan
patent: 2008/0311127 (2008-12-01), Schultes et al.
patent: 2009/0112163 (2009-04-01), Bivin et al.
patent: 2009/0202560 (2009-08-01), Madiyalakan et al.
patent: 2009/0291075 (2009-11-01), Eng et al.
patent: 0 153 871 (1984-09-01), None
patent: 0234122 (1987-09-01), None
patent: 0308208 (1989-03-01), None
patent: 315456 (1989-05-01), None
patent: 0315456 (1989-05-01), None
patent: 0288082 (1998-04-01), None
patent: 0553244 (1998-12-01), None
patent: WO 87/00053 (1987-01-01), None
patent: WO 88/03954 (1988-06-01), None
patent: WO-89/01629 (1989-02-01), None
patent: WO 89/05140 (1989-06-01), None
patent: WO 90/03142 (1990-04-01), None
patent: PCT/US90/03142 (1990-06-01), None
patent: WO 90/15626 (1990-12-01), None
patent: WO 92/11334 (1992-07-01), None
patent: PCT/US92/11334 (1993-07-01), None
patent: WO 93/12819 (1993-07-01), None
patent: WO 93/20185 (1993-10-01), None
patent: WO 94/01719 (1994-01-01), None
patent: PCT/EP94/01719 (1994-08-01), None
patent: WO 94/21287 (1994-09-01), None
patent: WO 94/27637 (1994-12-01), None
patent: WO 95/04548 (1995-02-01), None
patent: WO096/10400 (1996-04-01), None
patent: WO 97/42973 (1997-11-01), None
patent: WO 98/57661 (1998-12-01), None
patent: WO 99/65517 (1999-12-01), None
patent: WO 01/00245 (2001-01-01), None
patent: WO 01/07082 (2001-02-01), None
patent: WO 01/12217 (2001-02-01), None
patent: WO 01/59452 (2001-08-01), None
patent: WO 01/85204 (2001-11-01), None
patent: WO 02/076384 (2002-10-01), None
patent: WO 03/034977 (2003-05-01), None
patent: WO02004/032962 (2004-04-01), None
Clark (Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, 1993, pp. 4-5).
Henry et at (Clinical Pharmacokinetics, 1992, vol. 23, pp. 85-89).
Slapak and Kufe, ‘Principles of Cancer Therapy’, In: Harrison's Principles of Internal Medicine, 1994, Isselbacher et al, Ed.s, p. 1835.
Abstract of Bukowski et al (Journal of Immunotherapy with Emphasis on Tumor Immunology, May 1994, vol. 15, pp. 273-282).
Abstract of Stillwagon et al (International Journal of Radiation Oncology, Biology and Physics, 1991, vol. 20, pp. 65-71).
Masucci et al (Medical Oncology and Tumor Pharmacotherapy, 1991, vol. 8, pp. 207-220).
Frodin et al (Hybridoma, 1991, vol. 10, pp. 421-431).
Chachoua et al (Journal of Immunotherapy, 1994, vol. 16, pp. 132-141).
Segerling et al (Science, 1975, vol. 188, pp. 55-57.
Abe et al (Journal of Immunological Methods, 2002, vol. 270, pp. 227-233).
Balzer et al (Journal of Molecular Medicine, 1999, vol. 77, pp. 699-712).
Imoto et al (Int J Cancer, 2006, vol. 120, pp. 357-361).
Baars et al (British Journal of Cancer, 2002, vol. 86, pp. 1230-1234).
Abbas, et al., “Antigen presentation by B lymphocytes,” in Antigen Presenting Cells: Diversity, Differentiation, and Regulation, 1988, pp. 269-279.
Adams, et al., “Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopatholooical findings,” Eur J Nucl Med., 1988, vol. 25, No. 9, pp. 1277-1283.
“AltaRex Corp, (AXO) Reports Favorable OvaRex®, Phase II Trial Results”, Biospace, AltaRex Corp., Jan. 13, 2001, p. 1.
Alzona, et al., “IL-12 activates IFN-gamma production through the preferential activation of CD30+ T cells,” J Immunol., 1995, vol. 154, No. 1,1 pp. 9-16.
An, et al., “Biochemical and Functional Antigenic Mimicry by a Polyclonal Anti-Idiotypic Antibody for Chlamydial Exoglycolipid Antigen,” Pathobiology, 1997, vol. 65, pp. 229-240.
Andersson, et al., “Modulation of antigen-antibody complexations by immunoglobulins,” Scand J Immunol., 1995, vol. 42, No. 4, pp. 407-417.
Avigan, “Dendritic development, and potential immunotherapy”, Blood Reviews, 1999, vol. 11, pp. 51-64.
Barnd, et al., “Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells,” Proc Natl Acad Sci USA., 1989, vol. 86, No. 18, pp. 7159-7163.
Bartoloni, et al., “Assay, isolation and characterization of circulating immune complexes from serum of gastrointestinal cancer, stage III and IV melanoma and chronic inflammatory bowel disease patients,” Oncology, 1993, vol. 50, No. 1, pp. 27-34.
Baskin, et al, “Moloney Leukemia Virus-Induced Cell Surface Antigen Mimicry by Monoclonal Antibodies”, Immunol Res, 1995, vol. 14, pp. 29
Madiyalakan Ragupathy
Nicodemus Christopher F.
Noujaim Antoine A.
Schultes Birgit C.
Canella Karen
Quest Pharmatech Inc.
Sheridan & Ross P.C.
LandOfFree
Combination therapy for treating disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination therapy for treating disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy for treating disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4278743